Top Markets
Coin of the day
F-star Therapeutics, Inc. F-star Therapeutics, Inc.

F-star Therapeutics, Inc.

FSTX
Kedudukan dalam Saham #21013
F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated... F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to inventing tetravalent bispecific antibodies for the treatment of cancer, particularly within the field of immuno-oncology. The company's primary investigational product, FS118, is currently in a Phase 2 proof-of-concept trial, evaluating its efficacy in head and neck cancer patients who have acquired resistance to PD-1/PD-L1 therapies. F-star is also advancing FS222, a bispecific antibody designed to simultaneously target the costimulatory CD137 receptor and the inhibitory PD-L1 ligand, through its initial Phase 1 human clinical study. Moreover, two additional drug candidates, FS120 and SB 11285, are undergoing Phase 1 clinical evaluation for patients with advanced malignancies. Founded in 2002, F-star Therapeutics, Inc. has its corporate headquarters situated in Cambridge, United Kingdom.
Harga Saham
$7.12
Disegerakkan terakhir: 2023-03-08
Modal Pasaran
$117.03M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
GB
Perdagangan F-star Therapeutics, Inc. (FSTX)

Kategori

EPS untuk F-star Therapeutics, Inc. (FSTX)
EPS setakat 2026 TTM: 0
Menurut laporan kewangan terkini dan harga saham F-star Therapeutics, Inc., EPS semasa syarikat (TTM) adalah 0. Pada akhir tahun 2026, syarikat mempunyai EPS sebanyak 0 sama dengan EPS tahun 2026 iaitu 0.
Sejarah EPS untuk F-star Therapeutics, Inc. dari 2026 hingga 2026
EPS pada akhir setiap tahun
Tahun EPS Ubah
Tidak cukup data untuk tarikh yang disediakan.
EPS untuk syarikat atau pesaing yang serupa
Syarikat EPS Perbezaan EPS Negara
$17.32 -
US
$27.74 -
NL
$-7.98 -
US
$-5.29 -
AU
- -
CH